Literature DB >> 17258671

Subarachnoid haemorrhage.

Jan van Gijn1, Richard S Kerr, Gabriel J E Rinkel.   

Abstract

Subarachnoid haemorrhage accounts for only 5% of strokes, but occurs at a fairly young age. Sudden headache is the cardinal feature, but patients might not report the mode of onset. CT brain scanning is normal in most patients with sudden headache, but to exclude subarachnoid haemorrhage or other serious disorders, a carefully planned lumbar puncture is also needed. Aneurysms are the cause of subarachnoid haemorrhage in 85% of cases. The case fatality after aneurysmal haemorrhage is 50%; one in eight patients with subarachnoid haemorrhage dies outside hospital. Rebleeding is the most imminent danger; a first aim is therefore occlusion of the aneurysm. Endovascular obliteration by means of platinum spirals (coiling) is the preferred mode of treatment, but some patients require a direct neurosurgical approach (clipping). Another complication is delayed cerebral ischaemia; the risk is reduced with oral nimodipine and probably by maintaining circulatory volume. Hydrocephalus might cause gradual obtundation in the first few hours or days; it can be treated by lumbar puncture or ventricular drainage, dependent on the site of obstruction.

Entities:  

Mesh:

Year:  2007        PMID: 17258671     DOI: 10.1016/S0140-6736(07)60153-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  427 in total

Review 1.  Neurovascular events after subarachnoid hemorrhage: focusing on subcellular organelles.

Authors:  Sheng Chen; Haijian Wu; Jiping Tang; Jianmin Zhang; John H Zhang
Journal:  Acta Neurochir Suppl       Date:  2015

2.  Vascular Dysfunction in Brain Hemorrhage: Translational Pathways to Developing New Treatments from Old Targets.

Authors:  Paul A Lapchak; Qiang Wu
Journal:  J Neurol Neurophysiol       Date:  2011

3.  α7 nicotinic acetylcholine receptor agonist PNU-282987 attenuates early brain injury in a perforation model of subarachnoid hemorrhage in rats.

Authors:  Kamil Duris; Anatol Manaenko; Hidenori Suzuki; William B Rolland; Paul R Krafft; John H Zhang
Journal:  Stroke       Date:  2011-09-29       Impact factor: 7.914

Review 4.  Vascular smooth muscle cells in cerebral aneurysm pathogenesis.

Authors:  Robert M Starke; Nohra Chalouhi; Dale Ding; Daniel M S Raper; M Sean Mckisic; Gary K Owens; David M Hasan; Ricky Medel; Aaron S Dumont
Journal:  Transl Stroke Res       Date:  2013-10-10       Impact factor: 6.829

Review 5.  Inflammation and cerebral aneurysms.

Authors:  Koji Hosaka; Brian L Hoh
Journal:  Transl Stroke Res       Date:  2013-12-11       Impact factor: 6.829

Review 6.  Molecular imaging of cerebrovascular lesions.

Authors:  Nohra Chalouhi; Pascal Jabbour; Vincent Magnotta; David Hasan
Journal:  Transl Stroke Res       Date:  2013-10-23       Impact factor: 6.829

Review 7.  Tumor necrosis factor-α modulates cerebral aneurysm formation and rupture.

Authors:  Robert M Starke; Daniel M S Raper; Dale Ding; Nohra Chalouhi; Gary K Owens; David M Hasan; Ricky Medel; Aaron S Dumont
Journal:  Transl Stroke Res       Date:  2013-09-20       Impact factor: 6.829

Review 8.  CT perfusion and delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis.

Authors:  Charlotte H P Cremers; Irene C van der Schaaf; Emerens Wensink; Jacoba P Greving; Gabriel J E Rinkel; Birgitta K Velthuis; Mervyn D I Vergouwen
Journal:  J Cereb Blood Flow Metab       Date:  2013-11-27       Impact factor: 6.200

9.  Intracisternal administration of tissue plasminogen activator improves cerebrospinal fluid flow and cortical perfusion after subarachnoid hemorrhage in mice.

Authors:  Dominic A Siler; Jorge A Gonzalez; Ruikang K Wang; Justin S Cetas; Nabil J Alkayed
Journal:  Transl Stroke Res       Date:  2014-02-14       Impact factor: 6.829

10.  The utility of serum procalcitonin in distinguishing systemic inflammatory response syndrome from infection after aneurysmal subarachnoid hemorrhage.

Authors:  Emir Festic; Jason Siegel; Matthew Stritt; William D Freeman
Journal:  Neurocrit Care       Date:  2014-06       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.